Zantac and Generic Ranitidine

Rice Harbut Elliott LLP is investigating a possible class action lawsuit on behalf of persons who ingested medication sold in B.C. and Quebec which may pose serious health risks, after Health Canada became aware of an impurity, N-nitrosodimethylamine (NDMA), which has been detected in some drugs. NDMA is classified as a probable human carcinogen, which means long-term exposure to levels above what is considered safe could increase the risk of cancer.

There has recently been a voluntary recall of the following over the counter medications:

Company Product  Name/Active Pharmaceutical Ingredient (API) DIN Strength Lot Date added
Apotex Inc. Acid Reducer (ranitidine) sold under the brand names Equate and Selection 02296160 150 mg All lots September 25, 2019
Apotex Inc. Apo-Ranitidine Oral Solution 02280833 15 mg/mL All lots September 25, 2019
Apotex Inc. Apo-Ranitidine Tablet 150mg 00733059 150 mg All lots September 25, 2019
Apotex Inc. Apo-Ranitidine Tablet 300mg 00733067 300 mg All lots September 25, 2019
Pro Doc Limitée Ranitidine – 150 00740748 150 mg All lots September 25, 2019
Pro Doc Limitée Ranitidine – 300 00740756 300 mg All lots September 25, 2019
Sandoz Canada Sandoz Ranitidine 02243229 150 mg All lots September 17, 2019
Sandoz Canada Sandoz Ranitidine 02243230 300 mg All lots September 17, 2019
Sanis Health Inc. Ranitidine 02353016 150 mg All lots September 25, 2019
Sanis Health Inc. Ranitidine 02353024 300 mg All lots September 25, 2019
Sivem Pharmaceuticals ULC Ranitidine 02385953 150 mg NP4179
NP4183
NP4184
NP5656
NP5657
NT2721
NT2722
NT2724
NT2757
NT2762
NT2763
NT2764
NT2765
PJ2434
PJ2435
PV6243
PV6244
PV6245
September 25, 2019
Sivem Pharmaceuticals ULC Ranitidine 02385961 300 mg NP4177
NP4180
NT1365
PX8854
September 25, 2019

The Health Canada recall can be found here.

If you have purchased any affected products as listed above we would be interested in hearing from you. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

 

Note: You are not obliged to fill in this form to participate in this class action. If you choose to do so, you are not retaining RHE LLP to act on your behalf. Providing the information requested does not make you a client of RHE LLP. All information submitted will be treated as confidential and will only be released as required by law or as you may consent.

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing reception@rhelaw.com.